Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B in Perimenopausal Women.

Exclusion Criteria

• •• Postmenopause, including surgical menopause.
• •* Presence of hormone-dependent cancers;
• •* Presence of other cancers, not in full remission with no recurrence for 5 years or more;
• •* Planned hospitalization in the next 6 months;
• •* Presence of hormonally-active extragenital endocrine diseases (diabetes; diseases of thyroid, adrenal, pituitary) that require prolonged or life-long therapies
• •* Surgical interventions on sex organs or breasts, 1 year or less prior to the screening;
• •* Gynecological conditions that may require hormonal therapies or surgeries (uterine myoma, endometriosis, endometrial hyperplasia etc.);
• •* Currently undergoing or planning to utilize assisted reproductive technologies;
• •* Any abdominal surgeries within less than 3 months prior to the screening;
• •* HRT including MHRT or hormonal contraceptives - current or within less than 3 months prior to the screening;
• •* Psychiatric conditions;
• •* Patients taking any other dietary supplements that can affect climacteric syndrome within the last month before enrolling in the trial;
• •* High risk of non-compliance.